The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

A Burnley resident is highlighting three back streets in Burnley that they say are riddled with drugs and rubbish.

The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Advanced artificial intelligence genetics models have been successfully applied to Parkinson’s disease at CCGC.

Parkinson's disease primarily affects neurons in the brain that produce dopamine (depicted here). Now, RIKEN researchers have found that ...

Alterity shares double after the company claims “statistically significant and meaningful” phase II study results EBR Systems ...